← Back to Search

Other

TL-925 for Allergic Conjunctivitis

Phase 2
Recruiting
Research Sponsored by Telios Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3, 5 and 7 minutes after cac
Awards & highlights

Study Summary

This trial studies a drug (TL-925) to treat allergic conjunctivitis. 70 people will get the drug or a placebo and be monitored for effectiveness.

Who is the study for?
This trial is for adults over 18 with a history of eye allergies confirmed by a skin test. They must have good vision and react to an allergen challenge in both eyes. Participants should not have any other eye diseases, recent eye surgeries, or infections.Check my eligibility
What is being tested?
The study tests TL-925 against a placebo in the form of eye drops for allergic conjunctivitis. It's randomized, meaning people are put into the TL-925 or placebo group by chance, and neither they nor the researchers know who gets what (double-masked).See study design
What are the potential side effects?
While specific side effects aren't listed here, typical reactions to ophthalmic drugs can include temporary discomfort, redness or itching in the eyes, possible blurred vision or watery eyes immediately after use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3, 5 and 7 minutes after cac
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 5 and 7 minutes after cac for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Conjunctival redness
Ocular itching

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: TL-925 ArmActive Control1 Intervention
Subjects will be dosed in clinic on days of dosing.
Group II: Placebo ArmPlacebo Group1 Intervention
Subjects will be dosed in clinic on days of dosing.

Find a Location

Who is running the clinical trial?

Telios Pharma, Inc.Lead Sponsor
9 Previous Clinical Trials
1,309 Total Patients Enrolled
~44 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top